M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-12-03

AUTHORS

Paul M. McKie, Tomoko Ichiki, John C. Burnett

ABSTRACT

The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function–enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension. More... »

PAGES

62-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5

DOI

http://dx.doi.org/10.1007/s11906-011-0244-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012051007

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22135207


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aldosterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Natriuretic Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation, Preclinical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glomerular Filtration Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuresis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Circulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sympathetic Nervous System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Therapies, Investigational", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vasodilation", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKie", 
        "givenName": "Paul M.", 
        "id": "sg:person.01271304603.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271304603.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ichiki", 
        "givenName": "Tomoko", 
        "id": "sg:person.01100245546.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100245546.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burnett", 
        "givenName": "John C.", 
        "id": "sg:person.01001266776.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-3-540-68964-5_15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002318921", 
          "https://doi.org/10.1007/978-3-540-68964-5_15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041461900", 
          "https://doi.org/10.1038/ng.361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051687311", 
          "https://doi.org/10.1038/nrd2399"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/378065a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015449350", 
          "https://doi.org/10.1038/378065a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00109-010-0641-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045002962", 
          "https://doi.org/10.1007/s00109-010-0641-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt0806-942", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032133391", 
          "https://doi.org/10.1038/nbt0806-942"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.328", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035621233", 
          "https://doi.org/10.1038/ng.328"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12-03", 
    "datePublishedReg": "2011-12-03", 
    "description": "The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function\u2013enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11906-011-0244-5", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021183", 
        "issn": [
          "1522-6417", 
          "1534-3111"
        ], 
        "name": "Current Hypertension Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "keywords": [
      "atrial natriuretic peptide", 
      "renal blood flow", 
      "glomerular filtration rate", 
      "M-ANP", 
      "natriuretic peptide", 
      "filtration rate", 
      "blood flow", 
      "higher plasma atrial natriuretic peptide", 
      "plasma atrial natriuretic peptide", 
      "action of ANP", 
      "suppression of aldosterone", 
      "inhibition of aldosterone", 
      "BP-lowering action", 
      "sympathetic nervous system", 
      "blood pressure regulation", 
      "recent human studies", 
      "cardiorenal actions", 
      "systemic vasodilatation", 
      "renal function", 
      "antihypertensive agents", 
      "human hypertension", 
      "BP regulation", 
      "lower risk", 
      "human studies", 
      "hypertension", 
      "animal models", 
      "nervous system", 
      "clinical testing", 
      "pressure regulation", 
      "therapeutic potential", 
      "vasodilatation", 
      "aldosterone", 
      "diuresis", 
      "protein therapy", 
      "multiple mechanisms", 
      "therapy", 
      "inhibition", 
      "novel strategy", 
      "peptides", 
      "concomitant enhancement", 
      "proteolytic degradation", 
      "action", 
      "risk", 
      "association", 
      "role", 
      "regulation", 
      "rate", 
      "suppression", 
      "agents", 
      "fundamental role", 
      "testing", 
      "study", 
      "BP", 
      "reduction", 
      "mechanism", 
      "function", 
      "addition", 
      "development", 
      "strategies", 
      "enhancement", 
      "potential", 
      "characteristics", 
      "flow", 
      "model", 
      "system", 
      "degradation", 
      "properties", 
      "attractive characteristics"
    ], 
    "name": "M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy", 
    "pagination": "62-69", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012051007"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11906-011-0244-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22135207"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11906-011-0244-5", 
      "https://app.dimensions.ai/details/publication/pub.1012051007"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_551.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11906-011-0244-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      21 PREDICATES      114 URIs      99 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11906-011-0244-5 schema:about N1a97530f8eb14f278c37ded4028daeaa
2 N220e49df8b3d4ff0ba2225dc85a8e97e
3 N22cceae128b84ffe9ae27ce3dcd7965b
4 N24c2a1f41e2748c1ba38aa9987aeeafd
5 N3faed8779da7475eb36c8efe5b6cb347
6 N6daa8dbd4abe4634846ddc19da637ac2
7 N9a1241f4aeb443d9b79584a6b5aca729
8 N9da9df6c05204eb291f04cbaebee8a54
9 Nbcb227a5e6ec4b4abc0ec7fe9b5abf1c
10 Nc049e58666214345af4cbf643cebe6c2
11 Nd312a2edcb474f8eb39d8819ffed3bcc
12 Ndfbc518cf05c4436a1ee9ffc442a1874
13 Ne84e56bbf6e4482b8a0222e543867a10
14 Nfb79ff37117f4b009a314c8ed7ce9faf
15 anzsrc-for:11
16 anzsrc-for:1102
17 schema:author Nfb5c03c6078840778c079633c2aa2adc
18 schema:citation sg:pub.10.1007/978-3-540-68964-5_15
19 sg:pub.10.1007/s00109-010-0641-2
20 sg:pub.10.1038/378065a0
21 sg:pub.10.1038/nbt0806-942
22 sg:pub.10.1038/ng.328
23 sg:pub.10.1038/ng.361
24 sg:pub.10.1038/nrd2399
25 schema:datePublished 2011-12-03
26 schema:datePublishedReg 2011-12-03
27 schema:description The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function–enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N10e7f88e6552400d81418c864da5f03d
31 N2be4f068905b4b4db6ed3573c3340d15
32 sg:journal.1021183
33 schema:keywords BP
34 BP regulation
35 BP-lowering action
36 M-ANP
37 action
38 action of ANP
39 addition
40 agents
41 aldosterone
42 animal models
43 antihypertensive agents
44 association
45 atrial natriuretic peptide
46 attractive characteristics
47 blood flow
48 blood pressure regulation
49 cardiorenal actions
50 characteristics
51 clinical testing
52 concomitant enhancement
53 degradation
54 development
55 diuresis
56 enhancement
57 filtration rate
58 flow
59 function
60 fundamental role
61 glomerular filtration rate
62 higher plasma atrial natriuretic peptide
63 human hypertension
64 human studies
65 hypertension
66 inhibition
67 inhibition of aldosterone
68 lower risk
69 mechanism
70 model
71 multiple mechanisms
72 natriuretic peptide
73 nervous system
74 novel strategy
75 peptides
76 plasma atrial natriuretic peptide
77 potential
78 pressure regulation
79 properties
80 protein therapy
81 proteolytic degradation
82 rate
83 recent human studies
84 reduction
85 regulation
86 renal blood flow
87 renal function
88 risk
89 role
90 strategies
91 study
92 suppression
93 suppression of aldosterone
94 sympathetic nervous system
95 system
96 systemic vasodilatation
97 testing
98 therapeutic potential
99 therapy
100 vasodilatation
101 schema:name M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy
102 schema:pagination 62-69
103 schema:productId N8a6420bdee644c6da005c1e5ab1357c7
104 Nb0bdfcd076404f57a0fbdb8d57ea7b80
105 Ned67c5ad26a5410e964bb771d8b0ee50
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012051007
107 https://doi.org/10.1007/s11906-011-0244-5
108 schema:sdDatePublished 2022-08-04T16:59
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N3000fea28c284dbd97eba2e62cd35523
111 schema:url https://doi.org/10.1007/s11906-011-0244-5
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N10e7f88e6552400d81418c864da5f03d schema:issueNumber 1
116 rdf:type schema:PublicationIssue
117 N1a97530f8eb14f278c37ded4028daeaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antihypertensive Agents
119 rdf:type schema:DefinedTerm
120 N220e49df8b3d4ff0ba2225dc85a8e97e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Biological Availability
122 rdf:type schema:DefinedTerm
123 N22cceae128b84ffe9ae27ce3dcd7965b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Humans
125 rdf:type schema:DefinedTerm
126 N24c2a1f41e2748c1ba38aa9987aeeafd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Drug Evaluation, Preclinical
128 rdf:type schema:DefinedTerm
129 N2be4f068905b4b4db6ed3573c3340d15 schema:volumeNumber 14
130 rdf:type schema:PublicationVolume
131 N3000fea28c284dbd97eba2e62cd35523 schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 N3faed8779da7475eb36c8efe5b6cb347 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Natriuresis
135 rdf:type schema:DefinedTerm
136 N6daa8dbd4abe4634846ddc19da637ac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Hypertension
138 rdf:type schema:DefinedTerm
139 N8a6420bdee644c6da005c1e5ab1357c7 schema:name pubmed_id
140 schema:value 22135207
141 rdf:type schema:PropertyValue
142 N8f27e840a40d42939894611a6903298d rdf:first sg:person.01001266776.01
143 rdf:rest rdf:nil
144 N9a1241f4aeb443d9b79584a6b5aca729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Aldosterone
146 rdf:type schema:DefinedTerm
147 N9da9df6c05204eb291f04cbaebee8a54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Atrial Natriuretic Factor
149 rdf:type schema:DefinedTerm
150 Nb0bdfcd076404f57a0fbdb8d57ea7b80 schema:name doi
151 schema:value 10.1007/s11906-011-0244-5
152 rdf:type schema:PropertyValue
153 Nbcb227a5e6ec4b4abc0ec7fe9b5abf1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Vasodilation
155 rdf:type schema:DefinedTerm
156 Nc049e58666214345af4cbf643cebe6c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Sympathetic Nervous System
158 rdf:type schema:DefinedTerm
159 Nd312a2edcb474f8eb39d8819ffed3bcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Renal Circulation
161 rdf:type schema:DefinedTerm
162 Nd4f271c1b20047eab515355ddbb3bc45 rdf:first sg:person.01100245546.46
163 rdf:rest N8f27e840a40d42939894611a6903298d
164 Ndfbc518cf05c4436a1ee9ffc442a1874 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Therapies, Investigational
166 rdf:type schema:DefinedTerm
167 Ne84e56bbf6e4482b8a0222e543867a10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Glomerular Filtration Rate
169 rdf:type schema:DefinedTerm
170 Ned67c5ad26a5410e964bb771d8b0ee50 schema:name dimensions_id
171 schema:value pub.1012051007
172 rdf:type schema:PropertyValue
173 Nfb5c03c6078840778c079633c2aa2adc rdf:first sg:person.01271304603.22
174 rdf:rest Nd4f271c1b20047eab515355ddbb3bc45
175 Nfb79ff37117f4b009a314c8ed7ce9faf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Blood Pressure
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
182 schema:name Cardiorespiratory Medicine and Haematology
183 rdf:type schema:DefinedTerm
184 sg:journal.1021183 schema:issn 1522-6417
185 1534-3111
186 schema:name Current Hypertension Reports
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01001266776.01 schema:affiliation grid-institutes:grid.66875.3a
190 schema:familyName Burnett
191 schema:givenName John C.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01
193 rdf:type schema:Person
194 sg:person.01100245546.46 schema:affiliation grid-institutes:grid.66875.3a
195 schema:familyName Ichiki
196 schema:givenName Tomoko
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100245546.46
198 rdf:type schema:Person
199 sg:person.01271304603.22 schema:affiliation grid-institutes:grid.66875.3a
200 schema:familyName McKie
201 schema:givenName Paul M.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271304603.22
203 rdf:type schema:Person
204 sg:pub.10.1007/978-3-540-68964-5_15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002318921
205 https://doi.org/10.1007/978-3-540-68964-5_15
206 rdf:type schema:CreativeWork
207 sg:pub.10.1007/s00109-010-0641-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045002962
208 https://doi.org/10.1007/s00109-010-0641-2
209 rdf:type schema:CreativeWork
210 sg:pub.10.1038/378065a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015449350
211 https://doi.org/10.1038/378065a0
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/nbt0806-942 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032133391
214 https://doi.org/10.1038/nbt0806-942
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/ng.328 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035621233
217 https://doi.org/10.1038/ng.328
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/ng.361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041461900
220 https://doi.org/10.1038/ng.361
221 rdf:type schema:CreativeWork
222 sg:pub.10.1038/nrd2399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051687311
223 https://doi.org/10.1038/nrd2399
224 rdf:type schema:CreativeWork
225 grid-institutes:grid.66875.3a schema:alternateName Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA
226 Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA
227 schema:name Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA
228 Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...